Amarin Corp Plc (AMRN)

[KCSVEN]

Not necessarily, if the vast majority are scripts are for off label then Lovaza reps have a huge advantage. Vascepa reps need to be cautious as they still have approval for Anchor upcoming and cannot be caught selling in a way the FDA disapproves of as it could lead to repercussions such as a delay in approval.

So Vascepa reps are not selling to Anchor indication at all, and Lovaza reps are likely still pushing it.